Wikipedia

User:Mr. Ibrahem/Darolutamide

< User:Mr. Ibrahem
Mr. Ibrahem/Darolutamide
Clinical data
Trade namesNubeqa
Other namesDarramamide, ODM-201, BAY-1841788
AHFS/Drugs.comMonograph
MedlinePlusa619045
License data
Pregnancy
category
  • AU: X (High risk)
Routes of
administration		By mouth
Drug classNonsteroidal antiandrogen
Legal status
Legal status
Pharmacokinetic data
Bioavailability≤30%[2]
Protein bindingDarolutamide: 92%[2]
Ketodarolutamide: 99.8%[2]
MetabolismDehydrogenation (CYP3A4), glucuronidation (UGT1A9, UGT1A1)[2]
MetabolitesKetodarolutamide[2][4]
Elimination half-life16–20 hours[2][4]
ExcretionUrine: 63.4%[2]
Feces: 32.4%[2]
Identifiers
  • N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
Chemical and physical data
FormulaC19H19ClN6O2
Molar mass398.85 g·mol−1
3D model (JSmol)
  • C[C@@H](Cn1ccc(n1)c2ccc(c(c2)Cl)C#N)NC(=O)c3cc([nH]n3)C(C)O
  • InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
  • Key:BLIJXOOIHRSQRB-PXYINDEMSA-N
  (verify)

Darolutamide, sold under the brand name Nubeqa, is a medication used to treat prostate cancer.[2][3] Specifically it is used for non-metastatic castration-resistant prostate cancer (nmCRPC) together with surgical or medical castration.[2] The medication is taken by mouth twice per day with food.[2]

Common side effects include tiredness, pain in the arms and legs, and rash.[2] Other side effects may include infertility and low white blood cells.[6] Use during pregnancy by either the male or female may harm the baby.[2] It is a nonsteroidal antiandrogen (NSAA) and works by preventing androgens from binding to the androgen receptor.[6]

Darolutamide was patented in 2011.[7] It was approved for medical use in the United States in 2019 and Europe and Australia in 2020.[2][3][8] In the United Kingdom 4 weeks of medication costs the NHS about £4,000 as of 2021.[9] This amount in the United States is about 11,000 USD.[10]

References edit

  1. ^ "Nubeqa Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 4 March 2020. Archived from the original on 28 August 2021. Retrieved 16 August 2020.
  2. ^ a b c d e f g h i j k l m n o p q "Nubeqa- darolutamide tablet, film coated". DailyMed. 31 July 2019. Archived from the original on 17 October 2020. Retrieved 22 November 2019.
  3. ^ a b c "Nubeqa EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 29 October 2020. Retrieved 16 August 2020.
  4. ^ a b Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. (August 2014). "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial" (PDF). The Lancet. Oncology. 15 (9): 975–85. doi:10.1016/S1470-2045(14)70240-2. PMID 24974051. Archived (PDF) from the original on 1 December 2020. Retrieved 9 August 2021.
  5. ^ "Darolutamide (Nubeqa) Use During Pregnancy". Drugs.com. 17 September 2019. Archived from the original on 3 December 2020. Retrieved 16 August 2020.
  6. ^ a b "Darolutamide Monograph for Professionals". Drugs.com. Archived from the original on 23 November 2019. Retrieved 28 December 2021.
  7. ^ "Androgen receptor modulating compounds". Archived from the original on 3 September 2019. Retrieved 28 December 2021.
  8. ^ "AusPAR: Darolutamide". Therapeutic Goods Administration (TGA). 3 August 2020. Archived from the original on 21 September 2020. Retrieved 22 September 2020.
  9. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 991. ISBN 978-0857114105.
  10. ^ "Darolutamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 28 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Darolutamide&oldid=1214478276"